Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    thumbnail
    Making sense of the rapidly changing biosimilars landscape

    Strategies for adapting and achieving optimal market access

    thumbnail
    Building a comparative evidence base using network meta-analysis

    Methods, implementation and reporting

    FSA_thumbnail
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    oligonucleotides
    Insights into first-in-human study design of oligonucleotides

    27 May 2026. Register now.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Healthy participants Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Social media image
ICON Plc logo
ICON Plc

Clinical trials rely on strong collaboration across multiple roles, each with a clearly defined remit. Yet the distinction between Clinical Research Associates, Clinical Trial Assistants, and Site Management Associates i...

20 Jan
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

ICON is honoured to be recognised on TIME and Statista’s World’s Best Companies of 2025 list for the third consecutive year. This achievement is a testament to our people, our values, and our vision for a better future. ...

20 Jan
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

We’re celebrating a major milestone. ICON has been named one of TIME and Statista’s World’s Best Companies of 2025 — for the third year in a row. This recognition is all about our people, our purpose and our passion. Tha...

20 Jan
18
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Demographic Matching in Organ Impairment Studies: Why It Matters Organ impairment (OI) studies are critical for safe and effective drug development—but did you know that demographic matching can make or break the accurac...

20 Jan
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

While RWD and tokenisation introduce many efficiencies and benefits to long-term follow-up, there are also extremely stringent requirements for handling the associated data. Find out how to ensure secure long-term foll...

19 Jan
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

While RWD and tokenisation introduce many efficiencies and benefits to long-term follow-up, there are also extremely stringent requirements for handling the associated data. Find out how to ensure secure long-term foll...

19 Jan
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

On January 5th, 2026, on the occasion of the visit of Irish Prime Minister Mr. Micheál Martin to China, ICON China team attended a business dinner hosted by the Irish government in Beijing. The event was held at the join...

16 Jan
View post
Social media image
ICON Plc logo
ICON Plc

Missed our recent webinar from Symphony Health, an ICON plc company? The recording for Riding the data wave: How pharma can navigate disruptions in open claims is now available. Discover how life sciences organisatio...

16 Jan
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

Learn the pros and cons of different AI models for SaMDs. The right model and data training sets are essential to develop your AI-enabled device. Our latest whitepaper lays out the best practices for data and AI models...

16 Jan
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

What should you consider when choosing a training dataset for your AI-enabled SaMD? Our whitepaper has the answers. Learn about AI models and data best practices and plan for your FDA Pre-Sub. Download it today. https://...

16 Jan
2
View post
View webpage
ICON Plc facebook post
ICON Plc logo
ICON Plc

With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn ...

15 Jan
1
View post
View webpage
Social media image
ICON Plc logo
ICON Plc

With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn ...

15 Jan
View post
View webpage
  • Previous
  • 1
  • …
  • 30
  • 31
  • 32
  • …
  • 100
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies